NCT05788926CompletedPhase 1
A phase I of TG6050 in the treatment of patients with metastatic lung cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Jun 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 21 May 2024
- Start date
- 27 Mar 2023
- Lead sponsor
- Transgene
- Diseases
- Lung cancer
- NCT number
- NCT05788926
- EU CT number
- 2024-513093-22-00
- EudraCT number
- 2022-000841-34
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 36
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Bergonie Coordinator of this site? Confirm its status | Bordeaux | France | Completed |
| Hôpital La Timone - APHM Coordinator of this site? Confirm its status | Marseille | France | Completed |
| Hopital Européen George Pompidou Coordinator of this site? Confirm its status | Paris | France | Completed |
| CHU Rennes Pontchaillou Hospital Coordinator of this site? Confirm its status | Rennes Cedex 9 | France | Completed |
| Institut de Cancérologie de l'Ouest - site de Saint Herblain Coordinator of this site? Confirm its status | SAINT HERBLAIN | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.